We have located links that may give you full text access.
Proliferative cell nuclear antigen in postradiotherapy prostate biopsies.
International Journal of Radiation Oncology, Biology, Physics 1994 September 31
PURPOSE: To determine if staining for proliferative cell nuclear antigen (PCNA) can distinguish between biologically active and inactive "residual tumor" in postradiotherapy prostate biopsies by correlating PCNA staining with clinical outcome.
METHODS AND MATERIALS: Since July 1990 all patients treated at the General Division of the Ottawa Regional Cancer Center with radical external beam radiotherapy for prostate cancer have had systematic transrectal ultrasound and transrectal ultrasound-guided biopsies beginning 12 months postradiotherapy. One hundred sixty-two patients have had 278 transrectal ultrasounds with four to seven biopsy specimens per examination. All biopsies were stained for prostate specific antigen and prostatic acid phosphatase. Keratin 903 was used to distinguish radiation atypia in benign glands from residual cancer. PCNA staining was done on all suspicious biopsies. Stage distribution was 31 T1b, 35 T2a, 61 T2b, and 35 T3-4. Median follow-up was 32 months (range 13-74).
RESULTS: Negative biopsies have been obtained in 83% of T1b and T2a tumors and 70% of T2b and T3-4. Twenty-six tumors have recurred locally (T1b: 10%, T2a: 3%, T2b: 21%, T3-4: 26%), six with concurrent distant metastases. Of these 26 local failures, 23 had positive PCNA (mean 15.4 nuclei per 100) and three could not be determined (insufficient tissue). In 34 patients showing residual carcinoma at the first postradiotherapy biopsy, subsequent negative biopsies were obtained at a median of 25 months. Proliferative cell nuclear antigen staining could be performed in 23 of these 34 patients. Sixty-five percent (15/23) were negative on the first biopsy, indicating a nonproliferative state. In those with PCNA positive residual on initial biopsy, none retained PCNA staining on subsequent negative biopsies. One patient with an initial PCNA negative biopsy has failed locally.
CONCLUSION: Proliferative cell nuclear antigen staining is useful in postradiotherapy prostate biopsies. Negative PCNA in a positive biopsy predicts (83-97%) for eventual resolution of tumor. Positive PCNA correlates with local failure (49-79%), but when present in an early biopsy (12-18 months), may still disappear.
METHODS AND MATERIALS: Since July 1990 all patients treated at the General Division of the Ottawa Regional Cancer Center with radical external beam radiotherapy for prostate cancer have had systematic transrectal ultrasound and transrectal ultrasound-guided biopsies beginning 12 months postradiotherapy. One hundred sixty-two patients have had 278 transrectal ultrasounds with four to seven biopsy specimens per examination. All biopsies were stained for prostate specific antigen and prostatic acid phosphatase. Keratin 903 was used to distinguish radiation atypia in benign glands from residual cancer. PCNA staining was done on all suspicious biopsies. Stage distribution was 31 T1b, 35 T2a, 61 T2b, and 35 T3-4. Median follow-up was 32 months (range 13-74).
RESULTS: Negative biopsies have been obtained in 83% of T1b and T2a tumors and 70% of T2b and T3-4. Twenty-six tumors have recurred locally (T1b: 10%, T2a: 3%, T2b: 21%, T3-4: 26%), six with concurrent distant metastases. Of these 26 local failures, 23 had positive PCNA (mean 15.4 nuclei per 100) and three could not be determined (insufficient tissue). In 34 patients showing residual carcinoma at the first postradiotherapy biopsy, subsequent negative biopsies were obtained at a median of 25 months. Proliferative cell nuclear antigen staining could be performed in 23 of these 34 patients. Sixty-five percent (15/23) were negative on the first biopsy, indicating a nonproliferative state. In those with PCNA positive residual on initial biopsy, none retained PCNA staining on subsequent negative biopsies. One patient with an initial PCNA negative biopsy has failed locally.
CONCLUSION: Proliferative cell nuclear antigen staining is useful in postradiotherapy prostate biopsies. Negative PCNA in a positive biopsy predicts (83-97%) for eventual resolution of tumor. Positive PCNA correlates with local failure (49-79%), but when present in an early biopsy (12-18 months), may still disappear.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app